Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadegiani, F.A., Goren, A., Wambier, C.G., McCoy, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262389/
https://www.ncbi.nlm.nih.gov/pubmed/34249367
http://dx.doi.org/10.1016/j.nmni.2021.100915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262389/
https://www.ncbi.nlm.nih.gov/pubmed/34249367
http://dx.doi.org/10.1016/j.nmni.2021.100915

Ejemplares similares